Cardium Therapeutics Inc.

Mr. Reinhard is a co-founder of Cardium and has served as a director and the Chief Executive Officer, President and Treasurer of Cardium since its inception in December 2003. Mr. Reinhard has also served as a director and the Chief Executive Officer and Treasurer of InnerCool Therapies, Inc. since March 2006, and as a director and the Chief Executive Officer and President of Tissue Repair Company since August 2006, each a wholly-owned subsidiary of Cardium. Previously, he served as a director and the Chief Executive Officer, President and Treasurer of Aries Ventures Inc. from October 20, 2005 through its merger with Cardium in January 2006. He also served as Chief Financial Officer of Aries Ventures Inc. from October 20, 2005 to November 16, 2005. For the past ten years, Mr. Reinhard has focused on the commercial development of cardiovascular growth factor therapeutics. Before founding Cardium, he was a co-founder of Collateral Therapeutics, Inc., a former Nasdaq listed public company, and served as a director (from 1995) and President (from 1999) of Collateral Therapeutics until the completion of its acquisition by Schering AG Group, Germany (Schering) in 2002. He continued as Chief Executive of Collateral Therapeutics through December 2004. Mr. Reinhard played a major role in effecting Collateral Therapeutics' initial public offering led by Bear Stearns & Co. in 1998, and the sale of Collateral Therapeutics to Schering. Mr. Reinhard has also been Executive Chairman (since 2004) of Artes Medical, Inc., a publicly-traded medical technology company. Previously, Mr. Reinhard was Vice President and Managing Director of the Henley Group, a publicly-traded diversified industrial and manufacturing group, and Vice President of various public and private companies created by the Henley Group through spin-out transactions, including Fisher Scientific Group, a leading international distributor of laboratory equipment and test apparatus for the scientific community, Instrumentation Laboratory and IMED Corporation, a medical device company. Mr. Reinhard received a B.S. in Finance and an M.B.A. from Babson College.

Array

Sir Aaron Klug , OM FRS is a member of the MRC Laboratory of Molecular Biology, Cambridge UK. He did much of the founding work on the structure of zinc finger DNA-binding proteins (ZFPs) and their interaction with DNA. He is the recipient of numerous honors and awards including the Nobel Prize for Chemistry. Sir Aaron was director of the MRC Laboratory of Molecular Biology from 1986-1996, and President of the Royal Society. He was a Founder and Director of Gendaq, a company founded in the United KIngdom to commercialize ZFPs and their various applications. Sangamo acquired Gendaq in 2001. Gabor M. Rubanyi, M.D., Ph.D. is Chief Scientific Officer of Cardium Therapeutics, Inc. Prior to joining Cardium in June 2006, he was Vice President and Head of the Gene Therapy Department at Berlex Biosciences in Richmond, California and Adjunct Professor of Molecular and Cellular Physiology at the University of California at Davis. He initiated and played a leading role in the Angiogenic Gene Therapy for Coronary Artery Disease project at Schering/Berlex. Formerly, he was Director of Vascular and Endothelial Research at Berlex (1992-1999), Director of the Institute of Pharmacology at Schering AG, Research Center, Berlin, Germany (1990-1992), Director of Pharmacology at Berlex Laboratories, Cedar Knolls, New Jersey (1987-1990) and Associate Professor at the Mayo Clinic Medical School, Rochester, Minnesota (1983-1987). The author and co-author of 22 books and over 325 research articles, he serves as an editorial board member for several biomedical journals and is a member of numerous American and international scientific societies. He is the Founder of the biomedical journal Endothelium. His pioneering work on the nature and characterization of endothelium-derived relaxing and contracting factors contributed in a significant way to our present knowledge about endothelial control of vascular function in health and disease.

Mr. Mulroy has served as Chief Financial Officer of Cardium Therapeutics, Inc., a publicly-traded medical technology company, since November 2005 and as a director and Chief Financial Officer of InnerCool Therapies since it was acquired by Cardium in March 2006. Mr. Mulroy has over 20 years of corporate financial experience spanning several industries, having served most recently as Chief Financial Officer at Molecular Imaging Corporation, a publicly-traded diagnostic services company. Previously he held senior financial positions at public and privately-held companies, including SeraCare Life Sciences, Bioceutix Inc., Bidland Systems, First World Communications, River Medical Inc., IVAC Corp., Spectragrahics Corp. and IMED Corp. He is a Certified Public Accountant in the State Of California and began his career with Ernst & Young. Mr. Mulroy earned his degree in business administration from the University of San Diego.

Gabor M. Rubanyi, M.D., Ph.D. is Chief Scientific Officer of Cardium Therapeutics, Inc. Prior to joining Cardium in June 2006, he was Vice President and Head of the Gene Therapy Department at Berlex Biosciences in Richmond, California and Adjunct Professor of Molecular and Cellular Physiology at the University of California at Davis. He initiated and played a leading role in the Angiogenic Gene Therapy for Coronary Artery Disease project at Schering/Berlex. Formerly, he was Director of Vascular and Endothelial Research at Berlex (1992-1999), Director of the Institute of Pharmacology at Schering AG, Research Center, Berlin, Germany (1990-1992), Director of Pharmacology at Berlex Laboratories, Cedar Knolls, New Jersey (1987-1990) and Associate Professor at the Mayo Clinic Medical School, Rochester, Minnesota (1983-1987). The author and co-author of 22 books and over 325 research articles, he serves as an editorial board member for several biomedical journals and is a member of numerous American and international scientific societies. He is the Founder of the biomedical journal Endothelium. His pioneering work on the nature and characterization of endothelium-derived relaxing and contracting factors contributed in a significant way to our present knowledge about endothelial control of vascular function in health and disease.

Dr. Engler was co-founder of Collateral Therapeutics and served as a Director from 1995 to 2000 and as Vice President -- Medical Director from 1995 through 1998. Currently, Dr. Engler is Professor of Medicine Emeritus at the University of California, San Diego (UCSD). He was Professor of Medicine at UCSD, Associate Chief of Staff for Research and Development at the Veterans' Affairs Medical Center, and a faculty member of the Institute for Biomedical Engineering at UCSD. He served as director of Coronary Care at the VA Hospital and was a clinical cardiologist until 2001 when he retired from UCSD and the VA Hospital to continue his work in the development of innovative agents for cardiovascular therapy. From 1985 to 1997, Dr. Engler was a Scientific Advisor to Gensia. Dr. Engler is a director of Halozyme Therapeutics, a publicly-traded biotechnology company. He received a B.A. in Physics from the University of North Carolina and his medical degree from Georgetown University.

Dr. Dylan is a co-founder of Cardium and has served as a director and the General Counsel, Executive Vice President and Secretary of Cardium since its inception in December 2003, and as the Chief Business Officer of Cardium since May 2005. Dr. Dylan has also served as a director and the Chief Business Officer, General Counsel, Executive Vice President and Secretary of InnerCool Therapies, Inc. since March 2006, and of Tissue Repair Company since August 2006, each a wholly-owned subsidiary of Cardium. Previously, he served as the Chief Business Officer, General Counsel, Executive Vice President and Secretary of Aries Ventures Inc. from October 20, 2005 through its merger with Cardium in January 2006. Dr. Dylan has focused on the development of cardiovascular growth factor therapeutics for the last eight years. He served as General Counsel (from 1998) and Vice President (from 1999) of Collateral Therapeutics, Inc. until the completion of its acquisition by Schering AG Group, Germany (Schering) in 2002. He continued as an executive officer of Collateral Therapeutics until October 2003. Dr. Dylan played a major role in developing Collateral Therapeutics' intellectual property portfolio, in furthering its business development efforts and in advancing the company toward and through its acquisition by Schering. In addition to his work with Collateral Therapeutics, Dr. Dylan has advised both privately-held and publicly-traded companies that are developing, partnering or commercializing technology-based products. Before joining Collateral Therapeutics, Dr. Dylan was a partner of the international law firm of Morrison & Foerster LLP. In his law firm practice, Dr. Dylan focused on the development, acquisition and enforcement of intellectual property rights, as well as related business and transactional issues. He also has worked with both researchers and business management in the biotech and pharmaceutical industries. Dr. Dylan received a B.Sc. in Molecular Biology from McGill University, Montreal, Canada, a Ph.D. in Biology from the University of California, San Diego, where he performed research at the Center for Molecular Genetics, and a J.D. from the University of California, Berkeley.

Dr. Sosnowski is Vice President, Biologics Development of Cardium Therapeutics and was appointed Chief Operating Officer of Tissue Repair Company following Cardium's acquisition of Tissue Repair Company in August 2006. Prior to the acquisition, Dr. Sosnowski served as President and CEO of Tissue Repair Company. Dr. Sosnowski has more than than 18 years in the health care industry. From June 2001 to December 2004 she served as Vice President Research and Development of Selective Genetics Inc. a tissue repair company that developed wound repair, orthopedic and cardiovascular products. At Selective Genetics, she co-invented and helped develop the targeted gene therapy program, both viral and non-viral. Prior to Selective Genetics she was employed by Prizm Pharmaceuticals from October 1992. Prior to joining Prizm, Dr. Sosnowski was at Ligand Pharmaceuticals, where her efforts were focused on identification of small molecule inhibitors of osteoporosis. Dr. Sosnowski received her B.A. in Biological Sciences from the University of California, Berkeley and Ph.D. in Biological Sciences from Johns Hopkins University. She is also a registered patent agent.

Mr. McCutchen is Vice President, Business Development of Cardium Therapeutics and was appointed Vice President, Business Development of Tissue Repair Company following Cardium's acquisition of the company in August 2006. Prior to the acquisition, Mr. McCutchen served as Vice President and Chief Financial Officer of the Tissue Repair Company. Mr. McCutchen has over 15 years of financial and business management experience in the life sciences industry. Mr. McCutchen joined Selective Genetics (formerly "Prizm Pharmaceuticals") in 1993 and has been Vice President and CFO since 1994. Heading up Selective Genetics' financial activities he has overseen 7 rounds of venture and private financings totaling more than $60 million. He also managed the spinning out of non-core technology to form a new venture backed company as well as the merger forming Selective Genetics. He has been involved in multiple corporate partnering transactions with companies such as Chiron and Biomet. Prior to joining Selective Genetics, Mr. McCutchen held various finance positions, the most recent of which was with Viagene, Inc., one of the first gene therapy biotechnology companies acquired by Chiron Corporation. He started his finance career in the investment banking industry where he was engaged in equity and debt transactions for high technology and life science companies. Mr. McCutchen received his B.A. in psychology with pre-medical sciences from Wheaton College and M.B.A. from the University of Washington, with a concentration in finance.

Andrew Leitch's career spans 28 years in public accounting, including 20 years as a partner at Deloitte & Touche, as well as holding senior executive positions with a number of private companies. He was Vice Chairman of Deloitte's Management Committee in Hong Kong, and Director of Mergers and Acquisitions for all of Asia. He has lived and worked in Japan, Singapore, and Hong Kong prior to retiring from public practice and relocating to San Diego. Not one to slow down, Mr. Leitch currently serves as an independent Director and Chairman of the Audit Committee of several NASDAQ listed companies, including Wireless Facilities, Blackbaud, and Aldila Inc.

Dr. Basilico is the Jan Vilcek Professor of Molecular Pathogenesis and Chairman of the Department of Microbiology at New York University School of Medicine. After training in virology in Italy and the U.S., he dedicated the earlier part of his scientific career to the study of oncogenic viruses and how these viruses interact with the host cell machinery to induce malignant transformation of cells in culture and in vivo. He also carried out pioneering studies on the mechanisms by which somatic cell mutations influence cell cycle progression and the genes and gene functions regulating cell division. In more recent years, Dr. Basilico's work has focused on mechanisms through which signaling by growth factors of the fibroblast growth factor (FGF) family regulates cell proliferation and differentiation. During the course of this work, he discovered and cloned the gene for human FGF4, whose angiogenic activity mediates the therapeutic effects of Generx, Cardium's lead product candidate. Dr. Basilico has published widely in numerous scientific journals, holds a number of patents for inventions in the FGF field and has acted as a consultant to several biotechnology companies.

Dr. Gabrielson has more than 25 years of experience as a physician and faculty member at Johns Hopkins University. Currently, Dr. Gabrielson is a Professor of Pathology and Oncology at Johns Hopkins University School of Medicine, and Professor of Environmental Health Sciences at the Johns Hopkins University Bloomberg School of Public Health. He is also an attending physician at the Johns Hopkins Hospital and Bayview Medical Center. Dr. Gabrielson received his Bachelor of Science in Biology and Chemistry from the University of Illinois and M.D. from Northwestern University Medical School.

Dr. Perez is a Professor of Medicine at University of California at San Francisco (UCSF) and served as President and CEO of Berlex Biosciences (a subsidiary of Berlex Laboratories, the U.S. pharmaceutical affiliate of the Schering AG Group, Germany) from 2001 until May 2006. Dr. Perez is an author of over 110 research articles and is a member of a number of biomedical societies. After completing an internship and residency in internal medicine at Beth Israel-Mount Sinai Medical Center in New York, Dr. Perez was a Fellow in Rheumatology at New York University-Bellevue Medical Center. He served on the NYU faculty until he was recruited by UCSF to start the Rosalind Russell Arthritis Center at San Francisco General Hospital under the direction of Dr. Ira Goldstein.

Dr. Schatz has been the Research Director of Cardiovascular Interventions at the Heart, Lung, and Vascular Center and Co-Chairman of the Division of Cardiology at Scripps Clinic in La Jolla, California since 1990. Dr. Schatz is an early pioneer of coronary stent technology and is best known for the co-development of the first successful coronary stent, the Palmaz-Schatz stent. He is also active in gene and stem cell therapy research and teaches and lectures worldwide. Dr. Schatz served his internship and residency in Internal Medicine at Letterman Army Medical Center in San Francisco from 1977-1980. He did his cardiology fellowship at Brooke Army Medical Center at Fort Sam Houston, Texas, and was a member of the cardiology staff from 1982-1987and as acting chief of the cardiology service from 1986 to 1987. From July 1985 to June 1987 he also held the position of Clinical Associate Professor of Medicine at the University of Texas Health Sciences Center in San Antonio, Texas. In 1981, Dr. Schatz earned Board Certification in Internal Medicine. This was followed by Board Certification in Cardiology in 1983 with election as a Fellow, American College of Cardiology, in 1985.

Dr. Yla-Herttuala is Professor of Molecular Medicine at A.I. Virtanen Institute for Molecular Sciences and Department of Medicine, University of Kuopio, Kuopio, Finland. Dr. Yla-Herttuala is an internationally recognized leader in cardiovascular gene therapy. His team was among the first to use adenovirus-mediated gene transfer in human arteries and since then, he has conducted several clinical trials in cardiovascular gene therapy. His group is also widely recognized for basic and applied biology research related to vascular endothelial growth factors (VEGF), especially with newer members of the growth factor family. Dr. Yla-Herttuala serves on the editorial boards of several major US and European cardiovascular and gene therapy journals. He has published over 250 scientific papers and articles related to cardiovascular diseases, VEGF, atherosclerosis, restenosis and gene therapy.

Dr. Sessa is Vice Chairman and Professor of the Department of Pharmacology at the Yale School of Medicine. He is the incoming Director of the Vascular Biology and Transplantation Program at Yale. Dr. Sessa has achieved national and international recognition for the development and application of basic cellular and molecular biological techniques to study physiologically important questions in the cardiovascular system. The primary emphasis of his work focuses on the synthesis and functions of nitric oxide production in the vascular endothelium as it pertains to endothelial dysfunction, vascular remodeling and angiogenesis. Dr. Sessa received a Bachelors Degree in Pharmacy from the Philadelphia College of Pharmacy and Sciences, an MS at the University of Rhode Island and Ph.D. at New York Medical College. He then conducted post-doctoral work at the William Harvey Research Institute in London and the University of Virginia School of Medicine. Dr. Sessa has been recognized by a number of honors including the John J. Abel Award in Pharmacology from the American Society of Pharmacology and Experimental Therapeutics and the Robert Berne Distinguished Lectureship from the American Physiological Society.

Dr. Schaper is Director Emeritus of the Max-Planck Institute for Heart and Lung Research at Bad Neuheim, Germany and Professor of Physiology at the Justus-Liebig University of Giessen, Germany. Dr. Schaper has led pioneering studies on arteriogenesis and collateral development in ischemic heart disease and peripheral vascular disease and currently heads the Arteriogenesis Research Group in Bad Neuheim. He is the recipient of numerous prestigious science awards including the Order of Merit, Germany, 2005; the Carl-Ludwig Medal of the German Cardiac Society, 2000; and the Humboldt Prize, Belgium, 1998 and is a member of several international professional societies.